Colombian Supremo (Coffea arabica)

Colombian Supremo is a premium-grade Coffea arabica bean grown at high altitudes in Colombia, characterized by elevated concentrations of chlorogenic acids (CGA) and caffeine as its primary bioactive compounds. These compounds modulate glucose metabolism and adenosine receptor antagonism, respectively, contributing to the broader metabolic and cognitive effects associated with Arabica coffee consumption.

Origin & History

Colombian Supremo is a premium grade of Coffea arabica coffee beans from Colombia, specifically denoting the largest beans (screen size 17-18) selected for superior size and quality standards established in the 1960s. Grown at high altitudes (1,200-2,200 meters) in regions like Huila, Antioquia, and Cauca on small farms under shade trees in volcanic soil, the beans undergo wet processing involving fermentation, washing, and sun-drying.

Historical & Cultural Context

Colombian Supremo lacks documented historical use in traditional medicine systems. The research indicates it has been cultivated for modern culinary purposes since the 1960s rather than for medicinal applications in indigenous or folk medicine.

Health Benefits

• No specific health benefits documented for Colombian Supremo cultivar - research dossier contains no clinical trials
• General coffee benefits may apply based on broader Coffea arabica research (not cultivar-specific)
• Type 2 diabetes risk reduction noted in general coffee meta-analysis (PMID 28628481, n>1 million) but not specific to Colombian Supremo
• Cardiovascular benefits mentioned for generic coffee (PMID 30158048) but not tested for this cultivar
• No evidence quality can be assigned as no Colombian Supremo-specific studies exist

How It Works

Caffeine in Colombian Supremo acts as a competitive antagonist at adenosine A1 and A2A receptors, increasing dopaminergic and noradrenergic neurotransmission to enhance alertness and reduce perceived fatigue. Chlorogenic acids, particularly 5-caffeoylquinic acid, inhibit glucose-6-phosphatase and slow intestinal glucose absorption, thereby attenuating postprandial blood glucose spikes. Diterpenes such as cafestol and kahweol modulate bile acid metabolism and exhibit anti-inflammatory activity via NF-κB pathway inhibition.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses specific to Colombian Supremo coffee. While general coffee research exists (PMID 28628481 for diabetes risk reduction in over 1 million subjects; PMID 30158048 for cardiovascular benefits), none differentiate Colombian Supremo from generic Coffea arabica varieties.

Clinical Summary

No cultivar-specific clinical trials exist for Colombian Supremo; evidence is extrapolated from broader Coffea arabica and general coffee research. A 2014 meta-analysis of 28 prospective studies (PMID 28619997) found that 3–4 cups of coffee daily was associated with approximately a 25% reduction in type 2 diabetes risk, attributed largely to chlorogenic acid content. Separate meta-analyses have linked regular Arabica coffee consumption to modest reductions in all-cause mortality and cardiovascular disease risk, though effect sizes vary by preparation method and individual metabolism. The evidence base is observational in nature, limiting causal inference and making direct application to Colombian Supremo specifically premature.

Nutritional Profile

Colombian Supremo is a grade designation (screen size 17+) of Coffea arabica grown in Colombia, not a distinct cultivar per se, but a quality/size classification typically comprising Caturra, Castillo, Colombia, and Typica varieties. Nutritional and phytochemical data below reflect brewed Colombian Supremo Arabica coffee (per 240 mL/8 fl oz standard brew, approximately 10 g ground coffee extracted): **Macronutrients:** Calories ~2–5 kcal; protein ~0.3 g; total fat ~0.05 g; carbohydrates ~0.0–0.7 g; essentially zero fiber in brewed form (though spent grounds retain ~35% insoluble dietary fiber by dry weight). **Caffeine:** 80–120 mg per 8 fl oz (Arabica range; Colombian Supremo typically mid-range ~95 mg owing to larger bean size and medium roast preference). **Chlorogenic acids (CGAs):** Major bioactive class; total CGA content in green Colombian Supremo beans ~6.0–7.5 g/100 g dry weight. Dominant species: 5-O-caffeoylquinic acid (5-CQA, ~45–55% of total CGAs), 3-CQA, 4-CQA, 3,5-diCQA, 4,5-diCQA, and feruloylquinic acids. Brewed cup delivers approximately 70–200 mg total CGAs depending on roast degree (light > dark). Bioavailability: ~33% absorbed in small intestine; remainder metabolized by colonic microbiota to caffeic acid, dihydrocaffeic acid, and ferulic acid. **Trigonelline:** Green bean ~0.8–1.1 g/100 g; brewed cup ~40–65 mg. Partially converted to niacin (vitamin B3) during roasting (~0.5–1.0 mg nicotinic acid generated per cup at medium roast). **Diterpenes (cafestol & kahweol):** Present in coffee oil at ~0.5–1.2% of green bean weight. Cafestol ~2–6 mg and kahweol ~2–5 mg per 100 mL in unfiltered preparations; paper-filtered coffee retains <0.1 mg each per cup. Kahweol is notably higher in Arabica than Robusta (Robusta has near-zero kahweol). **Melanoidins:** Formed via Maillard reaction during roasting; constitute ~25% of dry weight of medium-roast brewed extract. Contribute antioxidant, prebiotic, and metal-chelating properties. Not individually quantified in standard nutrition panels. **Minerals (per 240 mL brewed):** Potassium ~116 mg (~2.5% DV); magnesium ~7–12 mg (~2–3% DV); phosphorus ~7 mg; manganese ~0.05 mg; chromium ~0.5–1.0 µg; trace amounts of calcium (~5 mg), sodium (~5 mg), zinc, iron, and copper. Polyphenol-mineral interactions may reduce iron bioavailability when consumed with meals (up to 39% inhibition of non-heme iron absorption). **Vitamins:** Niacin (B3) ~0.5–1.0 mg (from trigonelline degradation + inherent content); riboflavin (B2) ~0.18 mg (~14% DV); pantothenic acid (B5) ~0.6 mg (~12% DV); trace thiamine (B1) and folate. **Other bioactive compounds:** Caffeic acid ~1–5 mg/cup; ferulic acid ~1–3 mg/cup; p-coumaric acid (trace); N-methylpyridinium (NMP, formed during roasting) ~1–5 mg/cup — associated with reduced gastric acid secretion. **Volatile aroma compounds:** >800 identified across roasted coffee; Colombian Supremo is noted for relatively high concentrations of 2-furfurylthiol, 2-methylbutanal, and 3-methylbutanal contributing to its characteristically smooth, nutty, caramel profile. **Bioavailability notes:** Caffeine is nearly 100% bioavailable with Tmax ~30–60 min. CGA bioavailability is moderate (~33%) with significant inter-individual variation based on gut microbiome composition. Diterpene absorption is high (~70–100%) from unfiltered brews. Melanoidin bioavailability is low systemically but high for colonic fermentation (prebiotic effect). Overall antioxidant capacity (ORAC): ~2,500–3,000 µmol TE per 240 mL brewed cup, making it one of the highest antioxidant-delivering beverages per serving in the Western diet.

Preparation & Dosage

No clinically studied dosage ranges exist for Colombian Supremo in extract, powder, or standardized forms, as it is primarily a beverage cultivar without biomedical standardization. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research for Colombian Supremo

Safety & Interactions

Colombian Supremo, like all Coffea arabica preparations, carries risks associated with caffeine intake, including anxiety, insomnia, tachycardia, and elevated blood pressure at doses exceeding 400 mg caffeine per day in healthy adults. It may potentiate the effects of stimulant medications and interfere with adenosine-based therapies; it can also reduce the absorption of certain medications including bisphosphonates and some antibiotics when consumed simultaneously. Chlorogenic acid content may enhance the hypoglycemic effect of antidiabetic medications, warranting blood glucose monitoring in diabetic patients. Pregnant individuals are advised to limit total caffeine intake to under 200 mg per day per WHO guidelines, as higher intake is associated with increased risk of low birth weight.